Polycomb Repressive Complex 2 Is a Barrier to KRAS-Driven Inflammation and Epithelial-Mesenchymal Transition in Non-Small-Cell Lung Cancer

2016/01/01 by Michela Serresi, Gaetano Gargiulo, Natalie Proost +12 · 1 voice · 3 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Cancer Cells and Metastasis #Epigenetics and DNA Methylation #Hippo pathway signaling and YAP/TAZ

paper · pdf · doi:10.1016/j.ccell.2015.12.006

crossref issued 2016/01/01 · crossref published 2016/01/01 · crossref published-print 2016/01/01 · openalex publication_date 2016/01/01 · crossref created 2016/01/11 · openalex created_date 2025/10/10 · crossref deposited 2025/10/26 · crossref indexed 2026/03/18 · openalex updated_date 2026/07/28

Citations

• CBP-mediated acetylation of histone H3 lysine 27 antagonizesDrosophilaPolycomb silencing

Cited by

• Epigenomic State Transitions Characterize Tumor Progression in Mouse Lung Adenocarcinoma
• Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities
• Evolutionary fingerprints of epithelial-to-mesenchymal transition

Discussions

• 1/Previously: we reported an autochthonous model for LUAD: KPE, Kras G12D mut., p53 & PRC2 (Eed) loss → EMT, mucinous histopathology, ↑KRAS, metastasis vs. KP model. Aggressive regardless of lung cell [bsky, 3 points, 1 comments]